US-based bio-fabrication company Biological Lattice Industries (BLI) has announced that it has secured $1.8m in pre-seed investment aimed at driving the company’s goal of simplifying biofabrication for the global research and development (R&D) market.
The company said that the funds will be used to advance its all-in-one solution for biofabrication, dubbed BioLoom, as well as a multi-tool 3D bioprinter and Loominus Studio. Currently, biomaterials are used for resorbable medical devices and drug delivery systems for tissue trauma repair.
The pre-seed investment round was led by Greek venture capital company Uni.Fund. BLI’s AI-enabled software is designed to integrate all aspects of the biofabrication process from design to the fabrication itself with its software guiding the outcome of the 3D printed product.
Additionally, the company says that the compatible BioLoom 3D printer comes with Active Environmental Control aimed at appealing directly to the R&D market.
BLI founder and CEO Filippos Tourlomousis said: “We are thrilled to partner with Uni.Fund to bring our vision of democratising biofabrication to life. This funding will allow us to accelerate the development of our unified platform, enabling researchers to work with greater precision, reproducibility, and efficiency.
“Loominus Studio represents a new standard in biofabrication, allowing labs to focus on innovation rather than the technical challenges of integration. Our goal is to make biofabrication as simple and intuitive as possible, empowering researchers to break through technical barriers.”
Research by GlobalData found that by 2030, the 3D printing market will be worth $70.8bn, growing at a compound annual growth rate (CAGR) of 18.1% between 2021 and 2030. The same research concluded that bioprinting services will be the fastest-growing segment, with a CAGR of 25.7% between 2021 and 2030, outpacing software (22.0%), materials (15.9%), and hardware (13.7%).
Uni.Fund founding partner Katerina Pramatari said: “BLI is a game-changer in the biotech space, with a bold vision to disrupt how biofabrication is performed globally, heir integrated approach to life sciences R&D, combining sophisticated hardware and software powered by AI, is exactly the kind of innovation that Uni.Fund aims to support.”
Elsewhere in the field of 3D printing medical devices, US-based biotechnology company FluidForm Bio has made an advancement in 3D-printing human cardiac tissue.
